SEC Form 4 · accession 0001104659-17-015591

STEMLINE THERAPEUTICS INC · STML

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Chief Executive Officer · Director

Period of report

Mar 7, 2017

Accepted (ET)

Mar 9, 2017 · 9:32 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001264587

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F2,F3	Mar 7, 2017	S	5,401	$8.13	D	1,819,095	D
Common Stock^F4,F5	Mar 9, 2017	A	266,285	$0.00	A	2,085,380	D

No Table II lines on this filing.

F1In connection with the vesting of 12,565 shares on March 6, 2017, a total of 5,401 of such shares were sold by the Company in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies.
F2Reflects the weighted average sale price. The range of prices for such transaction is $8.05 to $8.15. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price.
F3Of the 1,819,095 shares, 165,906 are restricted stock.
F4The 266,285 restricted shares will vest in four installments as follows: 66,572 shares on March 9, 2018; 66,571 shares on March 9, 2019; 66,571 shares on March 9, 2020; and 66,571 shares on March 9, 2021.
F5Of the 2,085,380 shares, 432,191 are restricted stock.